Compare Stocks: IMA, GLSI, AKBA, and CAPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.88 +1.7%	$1.15	$0.82 ▼ $3.33	$240.97M	0.26	4.10 million shs	2.09 million shs
CAPR Capricor Therapeutics	$6.65 +58.0%	$18.18	$2.96 ▼ $40.37	$243.81M	0.54	7.00 million shs	65.95 million shs
GLSI Greenwich LifeSciences	$16.80 +2.6%	$18.58	$7.78 ▼ $34.10	$246.59M	1.46	174,683 shs	116,466 shs
IMA ImageneBio	$5.84 -0.5%	$5.79	$3.94 ▼ $15.27	$66.63M	0.76	11,245 shs	3,286 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+1.70%	-2.80%	-35.91%	-16.57%	-73.20%
CAPR Capricor Therapeutics	+57.96%	+62.59%	-67.32%	-76.90%	-19.88%
GLSI Greenwich LifeSciences	+2.56%	+16.99%	-14.02%	-38.26%	+42.61%
IMA ImageneBio	-0.51%	+2.64%	-2.83%	+2.82%	-58.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.88 +1.7%	$1.15	$0.82 ▼ $3.33	$240.97M	0.26	4.10 million shs	2.09 million shs
CAPR Capricor Therapeutics	$6.65 +58.0%	$18.18	$2.96 ▼ $40.37	$243.81M	0.54	7.00 million shs	65.95 million shs
GLSI Greenwich LifeSciences	$16.80 +2.6%	$18.58	$7.78 ▼ $34.10	$246.59M	1.46	174,683 shs	116,466 shs
IMA ImageneBio	$5.84 -0.5%	$5.79	$3.94 ▼ $15.27	$66.63M	0.76	11,245 shs	3,286 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	+1.70%	-2.80%	-35.91%	-16.57%	-73.20%
CAPR Capricor Therapeutics	+57.96%	+62.59%	-67.32%	-76.90%	-19.88%
GLSI Greenwich LifeSciences	+2.56%	+16.99%	-14.02%	-38.26%	+42.61%
IMA ImageneBio	-0.51%	+2.64%	-2.83%	+2.82%	-58.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.33	Hold	$3.75	324.02% Upside
CAPR Capricor Therapeutics	2.00	Hold	$29.15	338.35% Upside
GLSI Greenwich LifeSciences	2.33	Hold	$57.00	239.29% Upside
IMA ImageneBio	2.00	Hold	$30.00	413.70% Upside

Current Analyst Ratings Breakdown

Latest IMA, GLSI, AKBA, and CAPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/12/2026	GLSI Greenwich LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/7/2026	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$1.00
8/6/2026	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/31/2026	CAPR Capricor Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$2.00
7/30/2026	CAPR Capricor Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/30/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$3.50
7/30/2026	CAPR Capricor Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/28/2026	CAPR Capricor Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$7.00

(Data available from 8/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$236.20M	1.04	N/A	N/A	$0.09 per share	9.83
CAPR Capricor Therapeutics	$22.27M	17.29	N/A	N/A	$5.53 per share	1.20
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.21 per share	N/A
IMA ImageneBio	$800K	82.86	N/A	N/A	$12.52 per share	0.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	N/A
CAPR Capricor Therapeutics	-$105.04M	-$2.32	N/A	N/A	N/A	N/A	-58.09%	-48.01%	N/A
GLSI Greenwich LifeSciences	-$19.36M	-$1.57	N/A	N/A	N/A	N/A	-793.81%	-295.32%	N/A
IMA ImageneBio	-$45.35M	-$4.58	N/A	N/A	N/A	N/A	-38.99%	-34.84%	N/A

Latest IMA, GLSI, AKBA, and CAPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/11/2026	Q2 2026	GLSI Greenwich LifeSciences	-$0.33	-$0.27	+$0.06	-$0.27	N/A	N/A
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million
8/5/2026	Q2 2026	IMA ImageneBio	-$0.90	-$0.63	+$0.27	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
IMA ImageneBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.35
CAPR Capricor Therapeutics	N/A	8.42	8.42
GLSI Greenwich LifeSciences	N/A	1.54	2.01
IMA ImageneBio	N/A	21.47	21.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
CAPR Capricor Therapeutics	21.68%
GLSI Greenwich LifeSciences	4.16%
IMA ImageneBio	75.00%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
CAPR Capricor Therapeutics	9.20%
GLSI Greenwich LifeSciences	51.47%
IMA ImageneBio	2.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	277.11 million	265.19 million	Optionable
CAPR Capricor Therapeutics	101	57.91 million	52.58 million	Optionable
GLSI Greenwich LifeSciences	3	14.68 million	7.12 million	Not Optionable
IMA ImageneBio	70	11.35 million	10.42 million	Not Optionable

IMA, GLSI, AKBA, and CAPR Headlines

Recent News About These Companies

ImageneBio, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026

August 6, 2026 | zonebourse.comZ

ImageneBio Reports Second Quarter 2026 Financial Results

August 5, 2026 | globenewswire.com

ImageneBio (NASDAQ:IMA) Trading Up 2.9% - Should You Buy?

July 28, 2026 | marketbeat.com

ImageneBio Strengthens Leadership with New CFO Appointment

July 23, 2026 | tipranks.com

ImageneBio Stock Short Interest Report | NASDAQ:IMA | Benzinga

July 7, 2026 | benzinga.com

ImageneBio Appoints Matt Robbins as General Counsel

July 7, 2026 | markets.businessinsider.com

ImageneBio Appoints Matt Robbins as General Counsel

July 7, 2026 | globenewswire.com

ImageneBio, Inc. Common Stock

June 27, 2026 | fxempire.comF

ImageneBio, Inc. Common Stock (IMA) SEC Filings

June 25, 2026 | nasdaq.com

ImageneBio Shareholders Back Directors and Governance Proposals

June 17, 2026 | tipranks.com

ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York

May 27, 2026 | globenewswire.com

ImageneBio (IMA) price target decreased by 18.75% to 13.26

May 15, 2026 | msn.com

ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

May 7, 2026 | globenewswire.com

ImageneBio Inc.

April 13, 2026 | barrons.com

IMA stock surges 24%, breaks 50-DMA for first time since February – what's driving the rally?

April 13, 2026 | msn.com

ImageneBio $30 Million Private Placement Ignites Stock

April 13, 2026 | benzinga.com

ImageneBio, Inc. Secures $30 Million in Private Placement Led by Coastlands Capital to Advance IMG-007 Development

April 13, 2026 | quiverquant.comQ

ImageneBio Announces $30 Million Private Warrant Financing

April 13, 2026 | tipranks.com

ImageneBio Announces $30 Million Private Placement

April 13, 2026 | globenewswire.com

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 17, 2026 | globenewswire.com

ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update

March 10, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IMA, GLSI, AKBA, and CAPR Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.88 +0.01 (+1.70%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.88 -0.01 (-0.95%)

As of 08/14/2026 07:55 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Capricor Therapeutics NASDAQ:CAPR

$6.65 +2.44 (+57.96%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$6.51 -0.14 (-2.15%)

As of 08/14/2026 08:00 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Greenwich LifeSciences NASDAQ:GLSI

$16.80 +0.42 (+2.56%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$16.81 +0.01 (+0.04%)

As of 08/14/2026 07:37 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

ImageneBio NASDAQ:IMA

$5.84 -0.03 (-0.51%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$5.84 +0.00 (+0.09%)

As of 08/14/2026 04:10 PM Eastern

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMA, GLSI, AKBA, and CAPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMA, GLSI, AKBA, and CAPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMA, GLSI, AKBA, and CAPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMA, GLSI, AKBA, and CAPR Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Capricor Therapeutics NASDAQ:CAPR

Greenwich LifeSciences NASDAQ:GLSI

ImageneBio NASDAQ:IMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMA, GLSI, AKBA, and CAPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMA, GLSI, AKBA, and CAPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMA, GLSI, AKBA, and CAPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IMA, GLSI, AKBA, and CAPR Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Capricor Therapeutics NASDAQ:CAPR

Greenwich LifeSciences NASDAQ:GLSI

ImageneBio NASDAQ:IMA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools